iiinova — where your digital self keeps evolving

Arch Biopartners @archbiopartners.com · 31/08/2026

📢 Arch has received central IRB approval of the protocol and related study documents for its Phase II CS-AKI trial of LSALT peptide, completing an important step toward activating U.S. clinical sites. Full release: www.archbiopartners.com/investor-hub... #AKI

August 31, 2026 – News Release: Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide

000

Arch Biopartners @archbiopartners.com · 11/08/2026

📢 Arch will expand its Phase II CS-AKI trial of LSALT peptide into the U.S. following interest from clinicians at five leading institutions. The expansion will support patient access and build awareness among American clinicians. Full release: archbiopartners.com/investor-hub/press-releases/ #AKI

News release header graphic:

August 11, 2026

Arch Biopartners to Expand Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial to the United States

000

Arch Biopartners @archbiopartners.com · 17/07/2026

🧪 Arch has engaged a U.S.-based bioengineering laboratory to accelerate its IL-32 CKD program. The research will support proprietary data generation and development of IL-32 drug candidates for DKD. Full news release: www.archbiopartners.com/investor-hub... #CKD #IL32 #ArchBiopartners

000

Arch Biopartners @archbiopartners.com · 22/05/2026

🚨 Royal Columbian Hospital (RCH), part of @fraserhealth.ca, has dosed its first patient in Arch Biopartners’ Phase II CS-AKI trial evaluating LSALT peptide. RCH is the 4th dosing site in Canada. 📖 www.archbiopartners.com/investor-hub... #AKI #CSAKI #NephSky #peptide #kidneycare

Cover image for Arch Biopartners News Release:

May 22, 2026 - Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

000

Arch Biopartners @archbiopartners.com · 30/04/2026

🚨 Royal Columbian Hospital (RCH), part of @fraserhealth.ca, has begun patient recruitment in Arch Biopartners’ Phase II CS-AKI trial evaluating LSALT peptide. RCH is the 4th recruiting site in Canada. 📖 Read the full release: www.archbiopartners.com/investor-hub... #AKI #CSAKI #NephSky

Cover Image: April 30, 2026, Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI

000

Arch Biopartners @archbiopartners.com · 24/03/2026

🚨 Arch announced @fraserhealth.ca has entered into a Clinical Trial Agreement with the Company to enable Royal Columbian Hospital to prepare for recruitment in the Phase II CS-AKI trial evaluating LSALT peptide. 📖 www.archbiopartners.com/investor-hub... #AKI #CSAKI #NephSky

March 24, 2026, News Release. Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

000

Arch Biopartners @archbiopartners.com · 20/03/2026

🚨 Arch Biopartners: St. Michael’s Hospital (Unity Health Toronto) has commenced patient dosing in the Phase II CS-AKI trial of LSALT peptide. 🧪 News also provides ongoing Phase II clinical trials updates. 📖 Full release: www.archbiopartners.com/investor-hub... #AKI #CSAKI #NephSky

March 20, 2026 - News Release: Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

010

Arch Biopartners @archbiopartners.com · 09/02/2026

🚨 New peer-reviewed publication in Inflammation Research identifies IL-32 as a lipid droplet-associated cytokine linked to tubular injury in DKD. The findings strengthen the scientific foundation for Arch Biopartners’ CKD Platform targeting IL-32 📖 archbiopartners.com/investor-hub #CKD #NephSky

000

Arch Biopartners @archbiopartners.com · 16/01/2026

🚨 Arch Biopartners announced the appointment of Dr. Patrick Vink, M.D., M.B.A., as Chairman of the Board, effective January 15, 2026. Dr. Vink brings extensive experience in global pharmaceutical leadership and governance. 📖 Full release: archbiopartners.com/investor-hub #ArchBiopartners #ArchNews

News Release - January 16, 2026 - Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

010

Arch Biopartners @archbiopartners.com · 16/12/2025

🚨 Arch Biopartners announced that St. Michael’s Hospital @unityhealthto.bsky.social received ethics approval to join the Phase II CS-AKI trial evaluating LSALT peptide. 🏥 4th Canadian site, 9th globally. 🔗 Read more (and share): www.archbiopartners.com/arch-biopart... #LSALTpeptide #AKI #CSAKI

December 16 2025, News Release: Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide

010

Arch Biopartners @archbiopartners.com · 05/11/2025

🚨 Arch Biopartners has announced that the @fraserhealth.ca Research Ethics Board has approved Royal Columbian Hospital to join its Phase II trial of LSALT peptide to prevent CS-AKI. 📖 Latest News at www.archbiopartners.com/investor-hub/ #AKI #CSAKI #KidneyCare #NephSky

November 5, 2025 - News Release

Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia

010

Arch Biopartners @archbiopartners.com · 17/09/2025

🚨 Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD). 🔬 Full News Release: archbiopartners.com/investor-hub/press-releases/ #KidneyCare #CKD #NephSky #ArchBiopartners

News Release September 17 2025: Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)

010

Arch Biopartners @archbiopartners.com · 10/09/2025

📊 A 2022 study in Kidney International (doi.org/10.1016/j.kint.2022.02.033) showed consistent AKI incidence and outcomes across Canada, Denmark, and the UK using harmonized KDIGO definitions. Supports the need for targeted kidney therapies. 🔬 archbiopartners.com/our-science #AKI #CSAKI #NephSky

Infographic from Clinical Investigation, Volume 101, Issue 6, p1271-1281June 2022.

Harmonization of epidemiology of acute kidney injury and acute kidney disease produces comparable findings across four geographic populations

Sawhney, Simon et al.

Kidney International, Volume 101, Issue 6, 1271 - 1281

010

Arch Biopartners @archbiopartners.com · 06/08/2025

Arch Biopartners’ CS-AKI Phase II clinical trial is now active at Toronto General Hospital, ranked Canada's #1 and #3 globally. First patient dosed in the trial at this leading cardiac research hospital. 🔗 dub.sh/first-patien... #ArchBiopartners #CSAKI #AKI #LSALTpeptide #clinicaltrials #ArchNews

News release headline, clinical trial update from Arch Biopartners, August 6, 2025.

Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury

000

Arch Biopartners @archbiopartners.com · 22/07/2025

🚨 Arch Biopartners now has two lead drug candidates in active Phase II trials: 🔹 Cilastatin: in the PONTIAK trial for drug-toxin-related AKI, now open for recruitment 🔹 LSALT peptide: cardiac surgery-associated AKI 🔗 archbiopartners.com/investor-hub... #AKI #Cilastatin #LSALTpeptide #ArchNews

000

Arch Biopartners @archbiopartners.com · 09/05/2025

📢 Arch Biopartners’ May 2025 Corporate Presentation –Covers the CS-AKI and PONTiAK Phase II trials targeting inflammation- and toxin-related AKI. 📽️ Download the presentation and subscribe for updates at the Arch Investor Hub: www.archbiopartners.com/investor-hub/ #ArchBiopartners #CSAKI #InvestorFAQ

000